YESAccepted97% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
This Phase 2 trial has already had a trial-specific public readout. Traws’ Feb. 19, 2026 release/8-K says the completed analysis confirmed a differentiated profile vs PAXLOVID, with fewer adverse events, no viral rebounds, equivalent symptom resolution, and management called the data meaningful and supportive of continued development.
Found Apr 1, 2026, 6:50 PMOutcome date Feb 19, 2026, 12:30 PMReviewed Apr 1, 2026, 7:04 PM
ClinicalTrialsclinicaltrials.govFeb 1, 2026, 12:00 AM
Study Details | NCT07157007 | Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
ClinicalTrials.gov identifies NCT07157007 as the Phase 2 early-stage trial of ratutrelvir in mild-to-moderate COVID-19 sponsored by Traws Pharma.
Web Searchsec.govFeb 19, 2026, 12:30 PM
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients
Company 8-K exhibit says completed Phase 2 results confirmed a differentiated profile versus PAXLOVID with fewer adverse events, no viral rebounds, and equivalent time to sustained symptom resolution; CMO said the data were meaningful and support continued evaluation.